多嚢胞性卵巣症候群の世界市場：予測（2022年～2028年）

世界の多嚢胞性卵巣症候群の市場規模は、予測期間中に約4.0%CAGRで拡大すると予測されています。同市場の成長に寄与する主な要因は、座りがちなライフスタイルや誤った食習慣、世界の女性肥満人口の増加などが挙げられます。政府や非営利団体による、この疾患の早期診断に関する認識を広めるための取り組みが、市場の成長を大きく促進しています。

当レポートでは、世界の多嚢胞性卵巣症候群市場について調査し、市場の概要とともに、薬剤タイプ別、診断タイプ別、治療タイプ別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

第3章 競合情勢

• 主要企業分析
  • 概要
  • 財務分析
  • SWOT分析
• 主要戦略分析
• COVID-19が主要参入企業に与える影響

第4章 市場決定要因

• 促進要因
• 抑制要因
• 機会

第5章 市場セグメンテーション

• 世界の多嚢胞性卵巣症候群市場、薬剤タイプ別
  • 利尿薬
  • インスリン抵抗性改善剤
  • 抗アンドロゲン剤
  • 抗鬱剤
  • オルニチン脱炭酸酵素阻害剤
  • 抗肥満剤
  • 経口避妊剤
• 世界の多嚢胞性卵巣症候群市場、診断タイプ別
  • 超音波
  • 内診
  • 血液検査
• 世界の多嚢胞性卵巣症候群市場、治療タイプ別
  • 卵巣楔状切除術
  • 腹腔鏡下卵巣開孔術
  • 鍼治療
• 世界の多嚢胞性卵巣症候群市場、流通チャネル別
  • 院内薬局
  • 小売薬局（オンラインおよびオフライン）
  • 不妊治療クリニック

第6章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 企業プロファイル

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca plc
• AVA Science Inc.
• Bayer AG
• Bristol-Myers Squibb Co.
• Dexa Medica（Dexa Group）
• Ferring B.V.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Millendo Therapeutics, Inc.
• MyOva
• Novartis AG
• PCOS Diva LLC
• Pharmasure Ltd.
• Sanofi SA
• Sneha Natura
• Teva Pharmaceutical Industries Ltd.
• The Himalaya Drug Co.
• Theralogix, LLC

LIST OF TABLES

• 1. GLOBAL PCOS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
• 2. GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 3. GLOBAL INSULIN SENSITIZING AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL ANTIANDROGENS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 5. GLOBAL ANTI-DEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 7. GLOBAL ANTI-OBESITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 9. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2020-2027 ($ MILLION)
• 10. GLOBAL ULTRASOUND FOR PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL PELVIC EXAM FOR PCOS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 12. GLOBAL BLOOD TEST FOR PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 13. GLOBAL PCOS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
• 14. GLOBAL OVARIAN WEDGE RESECTION IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 15. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL ACUPUNCTURE IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 17. GLOBAL PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
• 18. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 19. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 20. GLOBAL FERTILITY CLINICS IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 21. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 22. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
• 23. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2020-2027 ($ MILLION)
• 24. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
• 25. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
• 26. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 27. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
• 28. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2020-2027 ($ MILLION)
• 29. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
• 30. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
• 31. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 32. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
• 33. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE,2020-2027 ($ MILLION)
• 34. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
• 35. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
• 36. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 37. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
• 38. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE,2020-2027 ($ MILLION)
• 39. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
• 40. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL PCOS MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL PCOS MARKET BY SEGMENT, 2020-2027 (% MILLION)

• 3. RECOVERY OF GLOBAL PCOS MARKET, 2020-2027 (%)
• 4. GLOBAL PCOS MARKET SHARE BY DRUG TYPE,2020 VS 2027 (%)
• 5. GLOBAL PCOS MARKET SHARE BY DIAGNOSIS TYPE,2020 VS 2027 (%)
• 6. GLOBAL PCOS MARKET SHARE BY TREATMENT TYPE,2020 VS 2027 (%)
• 7. GLOBAL PCOS MARKET SHARE BY DISTRIBUTION CHANNEL,2020 VS 2027 (%)
• 8. GLOBAL PCOS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 9. GLOBAL DIURETICS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 10. GLOBAL INSULIN SENSITIZING AGENTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL ANTIANDROGENS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 12. GLOBAL ANTI-DEPRESSANTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 13. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 14. GLOBAL ANTI-OBESITY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL ULTRASOUND FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 17. GLOBAL PELVIC EXAM FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 18. GLOBAL BLOOD TEST FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 19. GLOBAL OVARIAN WEDGE RESECTION IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 20. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 21. GLOBAL ACUPUNCTURE IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 22. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 23. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 24. GLOBAL FERTILITY CLINICS IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 25. UK PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 26. FRANCE PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 27. GERMANY PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 28. ITALY PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 29. SPAIN PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 30. REST OF EUROPE PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 31. INDIA PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 32. CHINA PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 33. JAPAN PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 34. SOUTH KOREA PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 35. REST OF ASIA-PACIFIC PCOS MARKET SIZE, 2020-2027 ($ MILLION)
• 36. REST OF THE WORLD PCOS MARKET SIZE, 2021-2027($ MILLION)

Global Polycystic Ovary Syndrome (PCOS) Market Size, Share & Trends Analysis Report By Drug Type (Diuretics, Insulin Sensitizing Agents, Antiandrogens, Anti-Depressants, Ornithine Decarboxylase Inhibitors, and Others), By Diagnosis (Ultrasound, Pelvic Exam, and Others) By Treatment (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies (Online And Offline), And Fertility Clinics) Forecast, 2021-2027

The global market for PCOS is projected to have a considerable CAGR of around 4.0% during the forecast period. Polycystic ovary syndrome is a hormonal disorder observed in females of reproductive ages. The disorder causes the excessive production of hormones in the female body, which include testosterone or androgens, hormones that are primarily associated with the male reproductive system. PCOS includes a range of symptoms such as irregular menstrual cycle, trouble in getting pregnant, cyst formation in the ovaries, excessive body and facial hair, and pelvic pain, among others. Moreover, the early diagnosis of the disorder is highly recommended by the physicians, as untreated PCOS may often lead to high cholesterol, type-2 diabetes, heart disease, insulin resistance, and high blood pressure. Major factors contributing to the growth of the global polycystic ovary syndrome market include a sedentary lifestyle and faulty dietary habits and an increasing female obese population across the globe. Initiatives taken by the government and non-profit organizations to spread awareness regarding the early diagnosis of the disorder are significantly fueling the market growth.

Moreover, increasing genetic and hormonal disorder in the female population is a major cause for the increase of polycystic ovary syndrome patients across the globe. The cost associated with the treatment of PCOS is the major factor affecting the growth of the market. According to the National Institute of the Health report, the cost to the US healthcare system to identify and manage PCOS is approximately $4 billion annually. However, the lack of regulatory approved drugs for the treatment of PCOS and easy availability of generic and off-label drugs may restrain the growth of the global PCOS market. However, market players are focusing on the development of innovative and symptom-specific drugs that are expected to fuel market growth in the near future.

Impact of COVID-19 on Global PCOS Market

The COVID-19 pandemic negatively affected the global PCOS market. As lockdown was announced by the government of major economies due to which essentials services and transportation facilities were put on halt. On the other hand, many gynecological procedures and nonessential treatments for PCOS were postponed. Even the new products and launches of products and drugs for the treatment of PCOS were canceled. This led to a decline in market growth. Besides, disruption in raw material supply from China was also witnessed during the pandemic, due to which the various drug development companies experienced major loss and fewer products in the pipeline. All these factors affected the market growth.

Segmental Outlook

The global PCOS market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on drug type, the market is segmented into diuretics, insulin-sensitizing agents, antiandrogens, anti-depressants, ornithine decarboxylase inhibitors, anti-obesity, and oral contraceptive pills. Among these, the insulin-sensitizing agents hold a major share owing to the wide adoption of the drug for the treatment of insulin resistance, to prevent diabetes which is one of the major causes of PCOS. Based on the diagnosis, the market is further classified into ultrasound, pelvic exam, and blood test. Whereas, the treatment segment is categorized into ovarian wedge resection, laparoscopic ovarian drilling, and acupuncture. Similarly, based on distribution channels, the global PCOS market is segmented into hospital pharmacies, retail pharmacies (online and offline), and fertility clinics.

Global PCOS Market Share by Treatment, 2020 (%)

Global PCOS Market Share by Treatment

Laparoscopic Ovarian Drilling is Expected to Dominate the PCOS Market

Based on treatment, laparoscopic ovarian drilling dominated the market and it is projected to grow at significant CAGR during the forecast period. The rising prevalence of polycystic ovarian syndrome is the major factor driving the growth of the market. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome. The increasing prevalence of PCOS creating the demand for advanced and cost-effective treatments such as laparoscopic ovarian drilling. Laparoscopic ovarian drilling is a surgical treatment that can trigger ovulation in women having PCOS and can destroy the parts of ovaries by electrocautery or a laser. Pregnancy success rates in the first year in women after ovarian drilling range surgery at around 50% according to the American Society for Reproductive Medicine. Due to these factors, the segment is expected to grow during the forecast period.

Regional Outlook

Geographically, the global PCOS market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is projected to exhibit the fastest growth in the global PCOS market during the forecast period. This is due to the large pool of female obese population in the region, especially in China. The presence of a large patient pool, government awareness programs regarding the growing prevalence of PCOS, and advancement in cost-effective treatments for PCOS are the major factors driving the growth of the market during the forecast period.

Global PCOS Market Growth, by Region 2021-2027

Global PCOS Market Growth, by Region

North America Holds the dominant Position in the Global PCOS market

Geographically, North America held the largest share in 2020, and it is projected to dominate the market during the forecast period. This is mainly owing to the rising prevalence of PCOS disorder, and the large presence of the obese female population. According to the CDC, in the US, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of Women. This increasing prevalence creating the strong demands for an effective treatment for PCOS. Moreover, high reimbursement policies by the government in the healthcare sector and awareness amongst the population regarding the early diagnosis of the disorder, and adoption of minimal invasive surgeries (MIS) are significantly contributing towards the market growth in the region.

Market Players Outlook

The key players in the global PCOS market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals, Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, FDA approvals, and geographical expansions to generated more revenue and to remain competitive in the market. For instance, in January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with Celmatix Inc., to develop multiple clinical candidates for the treatment of PCOS. Through this agreement, both companies contributed drug targets and a comprehensive set of high-quality technology platforms to develop innovative treatment options for PCOS.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Polycystic Ovary Syndrome (PCOS) market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global PCOS Industry
• Recovery Scenario of Global PCOS Industry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
• 3.2. Key Strategy Analysis
• 3.3. Impact of COVID-19 on key players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global PCOS Market, By Drug Type
  • 5.1.1. Diuretics
  • 5.1.2. Insulin Sensitizing Agents
  • 5.1.3. Antiandrogens
  • 5.1.4. Anti-Depressants
  • 5.1.5. Ornithine Decarboxylase Inhibitors
  • 5.1.6. Anti-Obesity
  • 5.1.7. Oral Contraceptive Pills
• 5.2. Global PCOS Market, By Diagnosis Type
  • 5.2.1. Ultrasound
  • 5.2.2. Pelvic Exam
  • 5.2.3. Blood Test
• 5.3. Global PCOS Market, By Treatment Type
  • 5.3.1. Ovarian Wedge Resection
  • 5.3.2. Laparoscopic Ovarian Drilling
  • 5.3.3. Acupuncture
• 5.4. Global PCOS Market, By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies (Online and Offline)
  • 5.4.3. Fertility Clinics

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Russia
  • 6.2.7. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korean
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World
  • 6.4.1. Latin America
  • 6.4.2. Middle East& Africa

7. Company Profiles

• 7.1. Abbott Laboratories
• 7.2. Astellas Pharma Inc.
• 7.3. AstraZeneca plc
• 7.4. AVA Science Inc.
• 7.5. Bayer AG
• 7.6. Bristol-Myers Squibb Co.
• 7.7. Dexa Medica (Dexa Group)
• 7.8. Ferring B.V.
• 7.9. GlaxoSmithKline plc
• 7.10. Merck & Co., Inc.
• 7.11. Millendo Therapeutics, Inc.
• 7.12. MyOva
• 7.13. Novartis AG
• 7.14. PCOS Diva LLC
• 7.15. Pharmasure Ltd.
• 7.16. Sanofi SA
• 7.17. Sneha Natura
• 7.18. Teva Pharmaceutical Industries Ltd.
• 7.19. The Himalaya Drug Co.
• 7.20. Theralogix, LLC